Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 6, 2004, Pages 503-504

  Basso, Igor Novitzky ^a   Keeling, David ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Myocardial infarction; Recombinant activated factor VII

Indexed keywords

BLOOD CLOTTING FACTOR 8; ESTROGEN; PROTON PUMP INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ANAMNESIS; ANGIODYSPLASIA; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; CASE REPORT; CLINICAL FEATURE; FEMINIZATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MALE; MELENA; PRIORITY JOURNAL; RISK FACTOR; VON WILLEBRAND DISEASE;

ANGIODYSPLASIA; ANTI-ULCER AGENTS; BLOOD TRANSFUSION; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; FACTOR VII; FACTOR VIII; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION; IRON; MALE; MELENA; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTON PUMPS; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASE;

EID: 4444346821     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200408000-00010     Document Type: Article

References (9)

1. Meijer K, Peters FT, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinolysis 2001; 12:211-213.
2. Poon MC, d'Oiron R, Hann I, Negrier C, de Lumley L, Thomas A, et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001; 38(suppl 12):21-25.
3. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75:981-982.
4. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9(suppl 1):S115-S118.
5. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41(suppl 1):101-108.
6. Rosendaal FR, Varekamp I, Smit C, Brocker-Vriends AH, van Dijck H, Vandenbroucke JP, et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71:71-76.
7. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769-771.
8. Sullivan DW, Purdy LJ, Billingham M, Glader BE. Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A. Pediatrics 1984; 74:279-281.
9. Hough RE, Hampton KK, Preston FE, Channer KS, West J, Makris M. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. Br J Haematol 2000; 111:974-979.